Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Heron Therapeutics (HRTX) just unveiled an announcement.
Heron Therapeutics, Inc. recently announced that the FDA has received its application for the extended-release solution ZYNRELEF® and set a review completion goal date for September 23, 2024. This milestone could signify a significant development for the company and holds potential implications for investors tracking advances in pharmaceuticals and Heron’s market position.
Learn more about HRTX stock on TipRanks’ Stock Analysis page.